Valneva says the European Medicines Agency accepted application for its COVID-19 vaccine

U.S.-listed shares of Valneva SE /zigman2/quotes/226552993/composite VALN -6.83% /zigman2/quotes/202377434/delayed FR:VLA -7.74% jumped 11.5% in premarket trading on Thursday after the company said that the European Medicines Agency has accepted the application of its COVID-19 vaccine candidate. If the experimental shot receives a positive recommendation from the EMA's Committee for Human Medicinal Products, the company said it expects a decision in June. The European Commission then decides whether to authorize the vaccine. Valneva's vaccine is an inactivated, whole-virus shot that was tested in clinical trials in Europe. Valneva's stock has slid 62.1% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX +1.06% has declined 17.7%.

/zigman2/quotes/226552993/composite

Add to watchlist VALN

Valneva SE ADR

US : U.S.: Nasdaq

$ 21.15

-1.55 -6.83%

Volume: 18,063

July 1, 2022 3:59p

P/E Ratio

N/A

Dividend Yield

N/A

Market Cap

$1.33 billion

Rev. per Employee

N/A

/zigman2/quotes/202377434/delayed

Add to watchlist FR:VLA

Valneva SE

FR : France: Euronext Paris

€ 10.02

-0.84 -7.74%

Volume: 1.07M

July 1, 2022 5:35p

P/E Ratio

N/A

Dividend Yield

N/A

Market Cap

€1.27 billion

Rev. per Employee

N/A

/zigman2/quotes/210599714/realtime

Add to watchlist SPX

S&P 500 Index

US : S&P US

3,825.33

+39.95 +1.06%

Volume: 2.20B

July 1, 2022 5:45p